OBJECTIVES: EPAG and ROMI are commonly used second line (2L) ITP treatments, however, there are limited published data on resource utilization and cost burden experienced by patients on these treatments in real world settings. We examined resource use and costs in ITP patients treated with EPAG and ROMI.

METHODS: This study used a syndicated electronic medical records network containing records for inpatient/outpatient services and procedures, disease diagnoses, AEs, prescription drugs and labs for over 29 million patients from 26 US hospital institutions. Adult patients diagnosed with primary ITP and treated with EPAG or ROMI were matched on age, prior steroid treatment, history of HBV/HCV/ HIV, malignancy, severe aplastic anemia, myelodysplastic syndrome, myelofibrosis and splenectomy. Resource use for treatment, administration, adverse events, rescue medication, platelet transfusion and routine care were collected over 12 months following treatment initiation. Unit costs obtained from various public sources were applied to calculate the annual total cost per treatment. 95% confidence intervals (CIs) were calculated for each resource use, except the drug costs, and used to calculate the CIs for the total costs.

RESULTS: CONCLUSIONS: This retrospective RWE study reports annual economic burden of ITP treatment. Total annual costs of treatment were significantly lower for EPAG vs. ROMI. Study limitations include reliance on electronic medical records with limited longitudinal data.